Xenon Pharmaceuticals (XENE) Financials

$57.72 +0.32 (+0.55%)

Closing price 03:59 PM Eastern

Extended Trading

$57.24 -0.48 (-0.82%)

As of 07:13 PM Eastern

Annual Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-16	-23	-31	-32	-40	-28	-77	-125	0.00	-236	-344
Consolidated Net Income / (Loss)	-16	-23	-31	-34	-42	-29	-79	-125	-182	-234	-346
Net Income / (Loss) Continuing Operations	-16	-23	-31	-34	-42	-29	-79	-125	-182	-234	-346
Total Pre-Tax Income	-16	-23	-32	-35	-42	-29	-79	-125	-183	-238	-345
Total Operating Income	-9.36	-25	-33	-38	-43	-31	-79	-129	-214	-279	-373
Total Gross Profit	16	1.80	0.31	-6.00	6.83	32	18	9.43	0.00	0.00	7.50
Total Revenue	16	1.80	0.31	0.00	6.83	32	18	9.43	0.00	0.00	7.50
Operating Revenue	16	1.80	0.31	-	6.83	32	18	9.43	0.00	0.00	7.50
Total Cost of Revenue	0.00	0.00	0.00	6.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	25	27	33	32	50	63	97	139	214	279	381
Selling, General & Admin Expense	9.79	6.79	7.31	8.41	11	13	22	33	47	69	80
Research & Development Expense	15	20	26	24	39	51	75	106	168	210	301
Total Other Income / (Expense), net	-6.39	1.82	0.48	3.52	1.20	2.20	0.11	3.89	31	41	28
Interest & Investment Income	0.54	0.50	0.48	1.22	2.35	2.28	0.47	8.71	28	42	27
Other Income / (Expense), net	-6.93	1.32	0.00	3.70	0.28	1.40	-0.36	-4.83	3.75	-1.06	1.35
Income Tax Expense	-	-	-	-0.02	-0.02	-0.26	-0.01	0.12	-0.29	-4.09	1.02
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-	-	-	-	-	-	1.54	-1.95
Basic Earnings per Share	($1.10)	($1.48)	($1.71)	($1.63)	($1.54)	($0.81)	($1.77)	($2.06)	($2.73)	($3.01)	($4.36)
Weighted Average Basic Shares Outstanding	14.28M	15.49M	17.99M	19.43M	25.94M	34.54M	43.63M	60.54M	66.89M	77.89M	79.25M
Diluted Earnings per Share	($1.10)	($1.48)	($1.72)	($1.63)	($1.54)	($0.81)	($1.77)	($2.06)	($2.73)	($3.01)	($4.36)
Weighted Average Diluted Shares Outstanding	14.28M	15.49M	18.00M	19.43M	25.94M	34.54M	43.63M	60.54M	66.89M	77.89M	79.25M
Weighted Average Basic & Diluted Shares Outstanding	14.30M	17.94M	18.00M	19.43M	25.94M	34.54M	43.63M	63.04M	75.43M	76.54M	83.19M

This table shows Xenon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-49	-48	-44	-50	-58	-59	-69	-64	-84	-91	-105
Consolidated Net Income / (Loss)	-47	-48	-45	-48	-58	-63	-66	-65	-85	-91	-105
Net Income / (Loss) Continuing Operations	-47	-48	-45	-48	-58	-63	-66	-65	-85	-91	-105
Total Pre-Tax Income	-48	-49	-45	-48	-58	-63	-70	-65	-85	-90	-105
Total Operating Income	-56	-56	-54	-59	-69	-74	-77	-73	-94	-96	-110
Total Operating Expenses	56	56	54	59	69	74	77	80	94	96	110
Selling, General & Admin Expense	12	13	13	15	19	17	18	19	19	19	22
Research & Development Expense	44	43	41	44	50	57	59	61	75	77	88
Total Other Income / (Expense), net	7.94	7.07	8.75	12	11	11	7.94	8.12	8.90	6.12	5.04
Interest & Investment Income	6.52	6.98	8.69	11	11	10	9.42	8.08	7.20	6.21	5.34
Other Income / (Expense), net	1.42	0.08	0.06	0.17	0.01	0.24	-1.48	0.04	1.70	-0.09	-0.30
Income Tax Expense	-0.22	-0.16	-0.21	0.41	-0.33	-0.32	-3.85	0.43	-0.63	0.68	0.54
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	1.69	0.44	-3.55	-	-0.78	-0.95	-0.36	0.14
Basic Earnings per Share	($0.72)	($0.73)	($0.65)	($0.62)	($0.75)	($0.81)	($0.83)	($0.83)	($1.07)	($1.15)	($1.31)
Weighted Average Basic Shares Outstanding	65.86M	66.00M	66.89M	77.59M	77.67M	77.93M	77.89M	78.69M	78.95M	79.25M	79.25M
Diluted Earnings per Share	($0.72)	($0.73)	($0.65)	($0.62)	($0.75)	($0.81)	($0.83)	($0.83)	($1.07)	($1.15)	($1.31)
Weighted Average Diluted Shares Outstanding	65.86M	66.00M	66.89M	77.59M	77.67M	77.93M	77.89M	78.69M	78.95M	79.25M	79.25M
Weighted Average Basic & Diluted Shares Outstanding	64.15M	65.43M	75.43M	75.47M	75.76M	76.24M	76.54M	76.73M	77.11M	77.28M	83.19M

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-13	-42	3.39	48	-43	20	131	-118	91	-5.93	56
Net Cash From Operating Activities	-18	-20	-29	-35	-4.71	-48	-70	-101	-151	-181	-279
Net Cash From Continuing Operating Activities	-18	-20	-29	-35	-4.71	-48	-70	-101	-151	-181	-279
Net Income / (Loss) Continuing Operations	-16	-23	-31	-34	-42	-29	-79	-125	-182	-234	-346
Consolidated Net Income / (Loss)	-16	-23	-31	-34	-42	-29	-79	-125	-182	-234	-346
Depreciation Expense	1.04	0.86	0.65	0.59	0.43	0.64	0.91	1.41	2.06	2.56	2.54
Non-Cash Adjustments To Reconcile Net Income	11	0.86	0.76	-1.13	2.54	6.23	11	23	24	54	62
Changes in Operating Assets and Liabilities, net	-14	1.71	0.56	0.03	33	-26	-2.59	-1.28	5.34	-3.15	2.46
Net Cash From Investing Activities	10	-48	24	-29	-66	-17	-247	-293	-111	165	218
Net Cash From Continuing Investing Activities	10	-48	24	-29	-66	-17	-247	-293	-111	165	218
Purchase of Property, Plant & Equipment	-0.55	-0.28	-0.32	-0.51	-1.24	-2.64	-2.05	-2.89	-5.62	-3.08	-0.80
Purchase of Investments	0.00	-48	-28	-77	-140	-229	-389	-551	-794	-532	-356
Sale and/or Maturity of Investments	11	0.00	53	49	76	215	145	261	688	700	574
Net Cash From Financing Activities	0.28	24	7.07	112	28	86	448	278	354	12	117
Net Cash From Continuing Financing Activities	0.28	24	7.07	112	28	86	448	278	354	12	117
Issuance of Common Equity	0.28	24	0.18	103	28	103	448	278	0.00	12	0.00
Other Financing Activities, net	-	-	-	-	-	-	-	0.71	354	0.05	117
Effect of Exchange Rate Changes	-5.74	1.89	0.75	-	0.41	-0.59	-0.59	-2.48	0.38	-1.67	0.46

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-4.96	35	49	-90	78	-49	55	-26	19	-31	95
Net Cash From Operating Activities	-33	-48	-35	-46	-33	-51	-54	-62	-64	-72	-81
Net Cash From Continuing Operating Activities	-33	-48	-35	-46	-33	-52	-54	-62	-64	-72	-81
Net Income / (Loss) Continuing Operations	-47	-48	-45	-48	-58	-63	-66	-65	-85	-91	-105
Consolidated Net Income / (Loss)	-47	-48	-45	-48	-58	-63	-66	-65	-85	-91	-105
Depreciation Expense	0.60	1.73	-0.63	0.59	0.66	0.67	0.63	0.66	0.63	0.64	0.61
Non-Cash Adjustments To Reconcile Net Income	6.97	7.95	4.58	6.70	15	12	6.54	16	17	14	15
Changes in Operating Assets and Liabilities, net	6.67	-3.45	-0.46	-5.55	9.76	-1.23	2.44	-13	2.77	4.60	8.19
Net Cash From Investing Activities	28	54	-240	-43	111	1.98	99	35	82	39	63
Net Cash From Continuing Investing Activities	28	54	-240	-43	111	1.98	99	35	82	39	63
Purchase of Property, Plant & Equipment	-2.13	-1.20	-0.08	-0.19	-1.51	-0.59	-0.78	-0.04	-0.16	-0.28	-0.32
Purchase of Investments	-162	-147	-377	-177	-125	-164	-66	-131	-89	-75	-61
Sale and/or Maturity of Investments	192	202	137	134	237	167	166	166	171	114	124
Net Cash From Financing Activities	-	30	324	0.00	-	-	12	1.15	0.07	2.36	114
Net Cash From Continuing Financing Activities	-	30	324	0.00	-	-	12	1.15	0.07	2.36	114
Other Financing Activities, net	-	-	-	0.00	-	-	-	1.15	0.07	2.36	114
Effect of Exchange Rate Changes	0.36	-0.29	0.25	-0.37	-0.20	-	-	-0.06	0.63	-0.01	-0.10

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	64	67	46	122	148	189	572	754	965	798	633
Total Current Assets	61	66	45	121	145	182	559	600	645	635	561
Cash & Equivalents	59	17	20	68	25	45	176	57	149	143	199
Short-Term Investments	0.00	47	23	52	117	132	376	535	489	484	350
Accounts Receivable	0.32	0.20	0.44	0.15	0.81	1.82	2.77	0.99	0.87	1.47	1.37
Prepaid Expenses	1.90	1.33	0.72	1.88	2.70	2.96	4.48	7.23	6.01	6.89	10
Plant, Property, & Equipment, net	1.99	1.40	1.07	0.99	1.66	3.55	4.47	6.50	9.65	10	8.72
Total Noncurrent Assets	1.09	0.41	0.23	0.11	1.17	3.85	8.52	147	310	153	64
Long-Term Investments	-	-	-	-	-	-	0.00	129	293	127	37
Noncurrent Deferred & Refundable Income Taxes	-	-	-	0.11	0.24	0.52	0.47	0.51	0.80	9.67	13
Other Noncurrent Operating Assets	1.09	0.41	0.23	-	0.93	3.33	8.06	18	17	15	14
Total Liabilities & Shareholders' Equity	64	67	46	122	148	189	572	754	965	798	633
Total Liabilities	2.92	3.59	10	19	56	18	22	33	37	43	51
Total Current Liabilities	2.78	3.59	4.08	4.12	43	15	14	23	27	36	42
Accounts Payable	2.63	3.59	3.38	4.12	8.82	11	14	22	26	34	40
Other Current Liabilities	-	-	-	-	0.17	0.27	0.61	0.49	1.30	1.37	1.53
Total Noncurrent Liabilities	0.13	0.00	6.10	15	12	3.05	7.65	9.95	9.60	7.65	9.61
Other Noncurrent Operating Liabilities	0.13	-	-	-	0.74	3.05	7.65	9.95	9.60	7.65	9.61
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	61	64	36	103	92	171	550	721	928	755	582
Total Preferred & Common Equity	61	64	36	103	92	171	550	721	928	755	582
Total Common Equity	61	64	36	96	84	164	542	721	928	755	582
Common Stock	182	208	210	304	335	443	901	1,207	1,593	1,656	1,827
Retained Earnings	-120	-143	-173	-208	-250	-278	-357	-483	-665	-899	-1,245
Accumulated Other Comprehensive Income / (Loss)	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	-3.00	-0.08	-1.61	0.34

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	776	720	685	671	919	884	836	743	674	608
Total Current Assets	649	533	545	531	707	728	660	566	500	480
Cash & Equivalents	103	70	65	100	59	137	88	117	135	105
Short-Term Investments	535	458	475	427	641	585	566	433	352	358
Accounts Receivable	2.48	2.22	2.12	0.81	0.83	0.85	0.94	8.65	1.10	0.81
Prepaid Expenses	8.51	4.09	2.89	3.53	6.77	5.70	4.69	7.26	12	17
Plant, Property, & Equipment, net	4.58	7.98	9.56	10	9.39	10	10	9.70	9.21	8.89
Total Noncurrent Assets	122	179	131	130	202	146	166	168	165	119
Long-Term Investments	114	160	113	112	186	129	149	141	137	93
Noncurrent Deferred & Refundable Income Taxes	0.51	0.22	0.45	0.60	0.40	0.73	1.05	11	11	12
Other Noncurrent Operating Assets	7.56	18	18	17	16	16	16	16	16	14
Total Liabilities & Shareholders' Equity	776	720	685	671	919	884	836	743	674	608
Total Liabilities	23	33	38	35	31	40	38	39	40	48
Total Current Liabilities	16	22	28	25	22	31	30	32	33	38
Accounts Payable	16	21	27	23	21	30	28	31	32	37
Other Current Liabilities	0.00	1.19	1.22	1.25	1.32	1.35	1.39	1.38	1.46	1.50
Total Noncurrent Liabilities	7.16	10	10	9.76	9.10	8.68	8.40	7.29	7.26	9.99
Other Noncurrent Operating Liabilities	7.16	10	10	9.76	9.10	8.68	8.40	7.29	7.26	9.99
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	753	687	646	637	888	844	798	704	634	560
Total Preferred & Common Equity	753	687	646	637	888	844	798	704	634	560
Total Common Equity	753	687	646	637	888	844	798	704	634	560
Common Stock	1,201	1,213	1,222	1,260	1,603	1,617	1,630	1,669	1,683	1,699
Retained Earnings	-445	-524	-572	-620	-713	-771	-834	-965	-1,049	-1,140
Accumulated Other Comprehensive Income / (Loss)	-2.96	-1.82	-3.30	-2.95	-1.77	-2.21	1.34	-0.84	0.11	0.48

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-45.09%	-88.43%	-82.75%	-100.00%	0.00%	371.02%	-42.68%	-48.83%	-100.00%	0.00%	0.00%
EBITDA Growth	-215.68%	-48.38%	-40.99%	-4.88%	-24.23%	30.15%	-170.09%	-67.94%	-58.07%	-32.80%	-32.89%
EBIT Growth	-230.88%	-44.23%	-38.61%	-5.43%	-23.86%	29.70%	-165.35%	-68.82%	-56.98%	-33.31%	-32.59%
NOPAT Growth	-159.00%	-165.11%	-31.26%	-16.78%	-12.56%	26.90%	-152.37%	-63.49%	-65.75%	-30.48%	-33.57%
Net Income Growth	-221.00%	-45.99%	-33.51%	-12.35%	-20.58%	30.67%	-173.54%	-58.94%	-45.48%	-28.48%	-47.62%
EPS Growth	-133.54%	-34.55%	-16.22%	5.23%	5.52%	47.40%	-118.52%	-16.38%	-32.52%	-10.26%	-44.85%
Operating Cash Flow Growth	-6,905.64%	-8.09%	-46.81%	-20.88%	86.42%	-920.87%	-44.42%	-45.36%	-49.57%	-20.04%	-53.88%
Free Cash Flow Firm Growth	-265.17%	27.00%	-50.02%	-20.08%	110.81%	-1,844.98%	-18.13%	-56.88%	-57.38%	-36.13%	-28.85%
Invested Capital Growth	121.16%	-110.28%	-279.18%	-7.32%	-3,294.38%	83.33%	69.14%	141.82%	-505.63%	117.00%	-952.19%
Revenue Q/Q Growth	-9.58%	-61.26%	-53.65%	-100.00%	95.11%	6.00%	-7.12%	-28.37%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-49.14%	-11.07%	-6.28%	-2.19%	-6.69%	-3.59%	-19.56%	-12.41%	-7.24%	-9.62%	-9.63%
EBIT Q/Q Growth	-45.64%	-10.01%	-6.12%	-2.47%	-6.57%	-3.19%	-19.41%	-12.98%	-6.55%	-9.93%	-9.13%
NOPAT Q/Q Growth	-39.24%	-13.02%	-8.63%	-1.07%	-7.92%	-4.42%	-17.76%	-16.71%	-5.09%	-9.31%	-9.48%
Net Income Q/Q Growth	-48.73%	-9.88%	-7.20%	-1.45%	-7.27%	-3.40%	-20.17%	-10.42%	-4.20%	-9.81%	-12.92%
EPS Q/Q Growth	-280.33%	-15.63%	-8.18%	6.32%	-5.48%	8.99%	-8.59%	-5.64%	-2.25%	-6.36%	-12.37%
Operating Cash Flow Q/Q Growth	-14.53%	2.86%	-8.16%	-1.18%	85.15%	-216.13%	-12.27%	-16.92%	-1.80%	-15.81%	-10.75%
Free Cash Flow Firm Q/Q Growth	0.00%	8.98%	-6.85%	-3.22%	111.86%	-199.77%	-7.29%	-17.43%	-5.04%	-13.16%	-3.24%
Invested Capital Q/Q Growth	335.94%	-34.62%	-97.24%	8.20%	-629.83%	36.64%	-153.79%	-22.96%	-18.64%	109.09%	-200.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	100.00%
EBITDA Margin	-97.94%	-1,255.52%	-10,262.06%	0.00%	-608.92%	-90.30%	-425.49%	-1,396.48%	0.00%	0.00%	-4,922.39%
Operating Margin	-60.10%	-1,376.43%	-10,474.28%	0.00%	-627.02%	-97.31%	-428.45%	-1,368.91%	0.00%	0.00%	-4,974.27%
EBIT Margin	-104.60%	-1,303.44%	-10,474.28%	0.00%	-622.89%	-92.97%	-430.41%	-1,420.06%	0.00%	0.00%	-4,956.29%
Profit (Net Income) Margin	-101.12%	-1,275.49%	-9,872.67%	0.00%	-609.09%	-89.65%	-427.85%	-1,328.95%	0.00%	0.00%	-4,612.13%
Tax Burden Percent	100.00%	100.00%	95.66%	99.93%	99.94%	99.12%	99.99%	100.09%	99.84%	98.29%	100.29%
Interest Burden Percent	96.67%	97.86%	98.54%	100.52%	97.84%	97.29%	99.41%	93.50%	86.87%	85.04%	92.78%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-1,625.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-1,615.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	1,588.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-23.54%	-36.81%	-61.51%	-49.55%	-42.60%	-21.90%	-21.87%	-19.72%	-22.12%	-27.85%	-51.76%
Cash Return on Invested Capital (CROIC)	-847.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12,756.74%	0.00%	-39,634.18%	0.00%
Operating Return on Assets (OROA)	-21.53%	-35.76%	-57.35%	0.00%	-31.49%	-17.75%	-20.85%	-20.20%	0.00%	0.00%	-51.94%
Return on Assets (ROA)	-20.81%	-34.99%	-54.05%	0.00%	-30.80%	-17.12%	-20.73%	-18.91%	0.00%	0.00%	-48.34%
Return on Common Equity (ROCE)	-23.54%	-36.81%	-61.51%	-46.80%	-39.23%	-20.62%	-21.40%	-19.60%	-22.12%	-27.85%	-51.76%
Return on Equity Simple (ROE_SIMPLE)	-25.81%	-35.99%	-85.45%	-33.40%	-45.22%	-16.83%	-14.34%	-17.38%	-19.66%	-31.04%	0.00%
Net Operating Profit after Tax (NOPAT)	-6.55	-17	-23	-27	-30	-22	-55	-90	-150	-196	-261
NOPAT Margin	-42.07%	-963.50%	-7,331.99%	0.00%	-438.91%	-68.12%	-299.91%	-958.24%	0.00%	0.00%	-3,481.99%
Net Nonoperating Expense Percent (NNEP)	-12.89%	-9.16%	-15.65%	-11.15%	-10.10%	-4.57%	-6.47%	-5.50%	-3.94%	-4.61%	-12.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-12.53%	-16.15%	-25.90%	-44.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	62.82%	376.71%	2,351.45%	0.00%	158.19%	40.24%	119.15%	347.78%	0.00%	0.00%	1,061.76%
R&D to Revenue	97.27%	1,099.72%	8,222.83%	0.00%	568.82%	157.07%	409.30%	1,121.13%	0.00%	0.00%	4,012.51%
Operating Expenses to Revenue	160.10%	1,476.43%	10,574.28%	0.00%	727.02%	197.31%	528.45%	1,468.91%	0.00%	0.00%	5,074.27%
Earnings before Interest and Taxes (EBIT)	-16	-24	-33	-34	-43	-30	-79	-134	-210	-280	-372
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-23	-32	-33	-42	-29	-78	-132	-208	-277	-369
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.89	2.16	1.42	1.67	4.03	3.29	2.97	3.42	3.25	3.96	5.95
Price to Tangible Book Value (P/TBV)	1.89	2.16	1.42	1.67	4.03	3.29	2.97	3.42	3.25	3.96	5.95
Price to Revenue (P/Rev)	7.42	76.42	163.49	0.00	49.66	16.74	87.41	261.41	0.00	0.00	461.80
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.89	0.00	0.00	0.00	0.00	0.00	0.00	2,397.45	0.00	4,450.58	0.00
Enterprise Value to Revenue (EV/Rev)	3.66	40.84	44.96	0.00	32.37	11.48	57.91	185.01	0.00	0.00	383.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	76.98	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.19	0.15	0.17	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.17	0.15	0.12	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.07	-0.98	-1.01	-1.01	-1.18	-1.15	-1.01	-1.00	-1.00	-1.00	-1.00
Leverage Ratio	1.13	1.05	1.14	1.21	1.38	1.28	1.06	1.04	1.04	1.05	1.07
Compound Leverage Factor	1.09	1.03	1.12	1.22	1.35	1.24	1.05	0.98	0.91	0.89	0.99
Debt to Total Capital	0.00%	0.00%	15.92%	12.69%	14.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	1.64%	0.00%	4.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	14.28%	12.69%	10.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	6.54%	7.19%	4.51%	1.41%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	84.08%	80.77%	78.36%	95.49%	98.59%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	-0.21	-0.45	-0.37	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	1.16	3.12	3.03	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	-0.19	-0.45	-0.26	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.30	-0.56	-0.52	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	1.62	3.92	4.20	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	-0.27	-0.56	-0.36	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	21.66	20.07	-3.53	2.84	1.21	16.76	43.85	44.77	48.12	39.64	36.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	5.55%	7.92%	5.87%	2.14%	0.61%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	21.88	18.31	10.98	29.46	3.34	12.30	39.03	26.44	23.65	17.85	13.42
Quick Ratio	21.20	17.94	10.80	29.00	3.28	12.10	38.72	26.12	23.43	17.66	13.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-15	-22	-27	2.87	-50	-59	-93	-146	-199	-256
Operating Cash Flow to CapEx	-3,285.48%	-7,013.26%	-9,119.37%	-6,848.92%	-380.16%	-1,824.95%	-3,390.34%	-3,490.95%	-2,690.26%	-5,898.83%	-34,933.42%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-19.05	2.00	-34.04	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-24.91	-3.29	-32.69	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-25.27	-4.15	-34.48	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.21	0.03	0.01	0.00	0.05	0.19	0.05	0.01	0.00	0.00	0.01
Accounts Receivable Turnover	58.78	7.00	0.97	0.00	14.17	24.41	8.04	5.03	0.00	0.00	5.28
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	6.98	1.06	0.25	0.00	5.15	12.34	4.60	1.72	0.00	0.00	0.79
Accounts Payable Turnover	0.00	0.00	0.00	1.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	6.21	52.13	374.39	0.00	25.76	14.95	45.40	72.56	0.00	0.00	69.11
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	228.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	6.21	52.13	374.39	0.00	25.76	14.95	45.40	72.56	0.00	0.00	69.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2.38	-0.25	-0.93	-1.00	-34	-5.64	-1.74	0.73	-2.95	0.50	-4.28
Invested Capital Turnover	-3.51	1.69	-0.53	0.00	-0.39	-1.63	-4.99	-18.63	0.00	0.00	-3.97
Increase / (Decrease) in Invested Capital	14	-2.63	-0.68	-0.07	-33	28	3.90	2.47	-3.68	3.46	-4.78
Enterprise Value (EV)	57	74	14	63	221	369	1,068	1,745	2,083	2,234	2,877
Market Capitalization	116	138	51	159	339	538	1,612	2,466	3,014	2,989	3,463
Book Value per Share	$4.25	$3.57	$2.00	$3.79	$3.26	$4.67	$10.51	$11.54	$14.18	$9.90	$7.53
Tangible Book Value per Share	$4.25	$3.57	$2.00	$3.79	$3.26	$4.67	$10.51	$11.54	$14.18	$9.90	$7.53
Total Capital	61	64	43	118	108	171	550	721	928	755	582
Total Debt	0.00	0.00	6.80	15	16	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	6.10	15	11	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-59	-64	-37	-104	-126	-177	-552	-721	-931	-754	-586
Capital Expenditures (CapEx)	0.55	0.28	0.32	0.51	1.24	2.64	2.05	2.89	5.62	3.08	0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.57	-2.06	-2.23	-2.09	-35	-10.00	-7.08	-14	-20	-27	-30
Debt-free Net Working Capital (DFNWC)	58	62	41	117	106	167	545	578	618	600	519
Net Working Capital (NWC)	58	62	41	117	101	167	545	578	618	600	519
Net Nonoperating Expense (NNE)	9.20	5.63	7.90	7.87	12	6.93	24	35	33	39	85
Net Nonoperating Obligations (NNO)	-59	-64	-37	-104	-126	-177	-552	-721	-931	-754	-586
Total Depreciation and Amortization (D&A)	1.04	0.86	0.66	0.87	0.95	0.86	0.91	2.22	2.06	3.81	2.54
Debt-free, Cash-free Net Working Capital to Revenue	-3.64%	-114.09%	-716.72%	0.00%	-515.76%	-31.07%	-38.38%	-153.60%	0.00%	0.00%	-400.39%
Debt-free Net Working Capital to Revenue	372.88%	3,443.65%	13,324.12%	0.00%	1,554.21%	519.19%	2,954.37%	6,122.49%	0.00%	0.00%	6,918.09%
Net Working Capital to Revenue	372.88%	3,443.65%	13,099.04%	0.00%	1,486.12%	519.19%	2,954.37%	6,122.49%	0.00%	0.00%	6,918.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.10)	($1.48)	($1.71)	($1.63)	($1.54)	($0.81)	($1.77)	($2.06)	($2.73)	($3.01)	($4.36)
Adjusted Weighted Average Basic Shares Outstanding	14.28M	15.49M	17.99M	19.43M	34.96M	35.81M	51.92M	60.54M	66.89M	77.89M	79.25M
Adjusted Diluted Earnings per Share	($1.10)	($1.48)	($1.72)	($1.63)	($1.54)	($0.81)	($1.77)	($2.06)	($2.73)	($3.01)	($4.36)
Adjusted Weighted Average Diluted Shares Outstanding	14.28M	15.49M	18.00M	19.43M	34.96M	35.81M	51.92M	60.54M	66.89M	77.89M	79.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.48)	($1.71)	($1.63)	($1.54)	($0.81)	($1.77)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.40M	17.94M	18.00M	25.75M	25.94M	34.54M	43.63M	63.04M	75.43M	76.54M	83.19M
Normalized Net Operating Profit after Tax (NOPAT)	-6.55	-17	-23	-27	-30	-22	-55	-90	-150	-196	-261
Normalized NOPAT Margin	-42.07%	-963.50%	-7,331.99%	0.00%	-438.91%	-68.12%	-299.91%	-958.24%	0.00%	0.00%	-3,481.99%
Pre Tax Income Margin	-101.12%	-1,275.49%	-10,320.90%	0.00%	-609.43%	-90.45%	-427.88%	-1,327.70%	0.00%	0.00%	-4,598.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-24.64	-29.66	-20.32	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	-19.10	-20.90	-14.89	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-25.00	-30.53	-22.11	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-19.47	-21.77	-16.68	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-69.42%	-33.19%	-34.25%	-25.31%	-27.67%	-35.09%	-40.43%	-23.60%	-34.25%	-31.62%	-39.81%
EBIT Growth	-69.32%	-36.27%	-31.73%	-25.64%	-27.47%	-32.08%	-47.20%	-23.49%	-33.92%	-31.30%	-39.40%
NOPAT Growth	-83.49%	-46.04%	-23.92%	-20.37%	-24.23%	-32.31%	-44.29%	-23.20%	-36.36%	-30.76%	-41.68%
Net Income Growth	-52.32%	-30.45%	-19.65%	-14.87%	-22.05%	-29.57%	-46.81%	-35.71%	-46.24%	-44.76%	-60.25%
EPS Growth	-30.91%	-28.07%	-10.17%	1.59%	-4.17%	-10.96%	-27.69%	-33.87%	-42.67%	-41.98%	-57.83%
Operating Cash Flow Growth	-96.95%	-58.14%	-0.20%	-25.48%	1.63%	-6.38%	-53.63%	-33.48%	-106.19%	-44.47%	-49.82%
Free Cash Flow Firm Growth	-59.74%	-25.51%	-3.37%	-46.22%	-33.41%	-36.55%	-70.15%	-39.89%	-71.68%	-59.08%	-24.91%
Invested Capital Growth	-134.56%	-363.39%	-505.63%	720.88%	-14.21%	-121.98%	117.00%	467.70%	239.48%	177.01%	-952.19%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%
EBITDA Q/Q Growth	-15.26%	-0.49%	-0.74%	-10.39%	-17.43%	-6.33%	-4.73%	5.47%	-27.56%	-4.23%	-14.27%
EBIT Q/Q Growth	-15.67%	-2.58%	3.53%	-9.76%	-17.36%	-6.29%	-7.51%	7.92%	-27.27%	-4.21%	-14.14%
NOPAT Q/Q Growth	-13.40%	-0.11%	3.57%	-9.96%	-17.04%	-6.62%	-5.16%	6.12%	-29.55%	-2.24%	-13.94%
Net Income Q/Q Growth	-13.74%	-2.11%	7.67%	-7.13%	-20.85%	-8.40%	-4.61%	0.97%	-30.22%	-7.31%	-15.80%
EPS Q/Q Growth	-14.29%	-1.39%	10.96%	4.62%	-20.97%	-8.00%	-2.47%	0.00%	-28.92%	-7.48%	-13.91%
Operating Cash Flow Q/Q Growth	3.46%	-44.72%	26.37%	-21.75%	24.32%	-56.51%	-6.33%	-13.36%	-4.19%	-11.71%	-13.56%
Free Cash Flow Firm Q/Q Growth	-18.59%	0.29%	4.61%	-29.63%	-8.20%	-2.06%	-18.86%	-6.58%	-32.79%	5.43%	6.68%
Invested Capital Q/Q Growth	-1,475.55%	56.60%	-18.64%	176.53%	-389.82%	15.65%	109.09%	2,455.78%	-28.79%	-53.43%	-200.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-960.59%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-969.84%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-969.37%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-867.29%	0.00%	0.00%	0.00%
Tax Burden Percent	99.54%	99.68%	99.54%	100.87%	99.43%	99.49%	94.47%	100.66%	99.27%	100.75%	100.51%
Interest Burden Percent	87.96%	87.44%	83.80%	80.71%	84.32%	85.94%	88.07%	88.88%	92.22%	93.56%	95.15%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-674.84%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-673.05%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	666.67%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-22.86%	-25.19%	-22.12%	-23.95%	-26.71%	-29.75%	-27.85%	-8.17%	0.00%	-45.14%	-51.76%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-7,055.52%	0.00%	0.00%	-39,634.18%	-2,858.40%	-2,609.13%	-5,836.10%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.75%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.83%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-22.86%	-25.19%	-22.12%	-23.95%	-26.71%	-29.75%	-27.85%	-8.17%	0.00%	-45.14%	-51.76%
Return on Equity Simple (ROE_SIMPLE)	-25.33%	-27.50%	0.00%	-21.25%	-23.58%	-26.75%	0.00%	-35.72%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-39	-39	-38	-41	-48	-52	-54	-51	-66	-67	-77
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-678.89%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.18%	-1.36%	-0.87%	-0.84%	-1.27%	-1.56%	-1.36%	-1.79%	-2.54%	-3.45%	-4.24%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-4.05%	-	-	-	-7.18%	-7.23%	-10.40%	-12.05%	-13.21%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	253.84%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	816.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,069.84%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-54	-56	-54	-59	-69	-73	-79	-73	-93	-96	-110
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-54	-54	-54	-58	-68	-73	-76	-72	-92	-96	-109
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.79	3.44	3.25	3.66	3.49	3.74	3.96	3.65	3.79	5.53	5.95
Price to Tangible Book Value (P/TBV)	3.79	3.44	3.25	3.66	3.49	3.74	3.96	3.65	3.79	5.53	5.95
Price to Revenue (P/Rev)	18,539.01	0.00	0.00	0.00	0.00	0.00	0.00	342.40	320.23	412.77	461.80
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	1,045.10	0.00	0.00	4,450.58	146.29	194.50	597.07	0.00
Enterprise Value to Revenue (EV/Rev)	13,598.16	0.00	0.00	0.00	0.00	0.00	0.00	250.25	236.92	338.74	383.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.00	-1.00	-1.00	-1.01	-1.01	-1.00	-0.99	-1.00	-1.00	-1.00
Leverage Ratio	1.04	1.04	1.04	1.04	1.05	1.05	1.05	1.04	1.05	1.06	1.07
Compound Leverage Factor	0.92	0.91	0.87	0.84	0.89	0.90	0.92	0.93	0.97	1.00	1.02
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	37.67	37.44	48.65	61.80	43.64	46.20	40.47	37.92	33.97	36.17	38.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	19.34	21.46	23.65	31.82	23.27	22.21	17.85	17.66	15.14	12.52	13.42
Quick Ratio	19.24	21.32	23.43	31.52	23.09	22.06	17.66	17.43	14.79	12.08	13.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-36	-36	-34	-44	-48	-49	-58	-61	-82	-77	-72
Operating Cash Flow to CapEx	-1,557.48%	-4,006.58%	-45,385.90%	-22,967.02%	-2,158.45%	-8,668.98%	-6,945.72%	-143,376.74%	-40,912.74%	-25,534.52%	-25,622.96%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01
Accounts Receivable Turnover	0.06	0.00	0.00	0.00	0.00	0.00	0.00	1.58	7.69	8.57	5.28
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.78	0.79	0.79
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	6,424.83	0.00	0.00	0.00	0.00	0.00	0.00	230.73	47.45	42.58	69.11
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	6,424.83	0.00	0.00	0.00	0.00	0.00	0.00	230.73	47.45	42.58	69.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-5.74	-2.49	-2.95	2.26	-6.55	-5.53	0.50	13	9.14	4.26	-4.28
Invested Capital Turnover	-0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.99	5.80	-11.81	-3.97
Increase / (Decrease) in Invested Capital	-3.29	-3.43	-3.68	2.62	-0.82	-3.04	3.46	11	16	9.78	-4.78
Enterprise Value (EV)	1,795	1,552	2,083	2,362	2,092	2,180	2,234	1,877	1,777	2,541	2,877
Market Capitalization	2,447	2,191	3,014	3,247	2,943	2,983	2,989	2,568	2,402	3,096	3,463
Book Value per Share	$10.17	$9.92	$14.18	$11.77	$11.18	$10.53	$9.90	$9.20	$8.26	$7.26	$7.53
Tangible Book Value per Share	$10.17	$9.92	$14.18	$11.77	$11.18	$10.53	$9.90	$9.20	$8.26	$7.26	$7.53
Total Capital	646	637	928	888	844	798	755	704	634	560	582
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-652	-639	-931	-885	-851	-803	-754	-691	-625	-555	-586
Capital Expenditures (CapEx)	2.13	1.20	0.08	0.19	1.51	0.59	0.78	0.04	0.16	0.28	0.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-20	-20	-15	-25	-24	-27	-16	-20	-20	-30
Debt-free Net Working Capital (DFNWC)	516	506	618	685	697	630	600	534	467	442	519
Net Working Capital (NWC)	516	506	618	685	697	630	600	534	467	442	519
Net Nonoperating Expense (NNE)	8.52	9.48	7.16	6.60	9.55	11	11	14	19	23	28
Net Nonoperating Obligations (NNO)	-652	-639	-931	-885	-851	-803	-754	-691	-625	-555	-586
Total Depreciation and Amortization (D&A)	0.60	1.73	-0.63	0.60	0.66	0.67	2.75	0.66	0.63	0.64	0.61
Debt-free, Cash-free Net Working Capital to Revenue	-17,532.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-214.96%	-271.20%	-272.88%	-400.39%
Debt-free Net Working Capital to Revenue	391,255.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7,113.43%	6,229.40%	5,890.69%	6,918.09%
Net Working Capital to Revenue	391,255.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7,113.43%	6,229.40%	5,890.69%	6,918.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.72)	($0.73)	($0.65)	($0.62)	($0.75)	($0.81)	($0.83)	($0.83)	($1.07)	($1.15)	($1.31)
Adjusted Weighted Average Basic Shares Outstanding	65.86M	66.00M	66.89M	77.59M	77.67M	77.93M	77.89M	78.69M	78.95M	79.25M	79.25M
Adjusted Diluted Earnings per Share	($0.72)	($0.73)	($0.65)	($0.62)	($0.75)	($0.81)	($0.83)	($0.83)	($1.07)	($1.15)	($1.31)
Adjusted Weighted Average Diluted Shares Outstanding	65.86M	66.00M	66.89M	77.59M	77.67M	77.93M	77.89M	78.69M	78.95M	79.25M	79.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	64.15M	65.43M	75.43M	75.47M	75.76M	76.24M	76.54M	76.73M	77.11M	77.28M	83.19M
Normalized Net Operating Profit after Tax (NOPAT)	-39	-39	-38	-41	-48	-52	-54	-51	-66	-67	-77
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-678.89%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-861.60%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise trend snapshot for Xenon Pharmaceuticals (XENE) using the last four years of quarterly statements. The company shows ongoing operating losses, essentially no revenue in recent periods, and a cash profile that has been supported largely by investing and financing activities rather than operations.

Q4 2025: Financing activities generated strong liquidity, with net cash from financing activities of $113,537,000.
Q4 2025: Investing activities produced a meaningful cash inflow, including $123,915,000 from sale/maturity of investments, contributing to a net cash from continuing investing activities of $62,697,000.
Q4 2025: Net change in cash and equivalents was a positive $94,649,000, supported by financing and investing inflows.
No debt on the balance sheet in recent quarters; total liabilities were around $48.3 million while total equity was about $559.5 million (Q3 2025), indicating a strong equity cushion relative to liabilities.

Revenue remains essentially zero across recent quarters (e.g., Q3 2025 shows Operating Revenue and Total Revenue at 0), highlighting that Xenon is still in a pre-revenue development phase.
R&D and SG&A continue to drive costs, with 2025 Q4 total operating expenses at $109.767 million (SG&A $22.068 million; RD $87.699 million), indicating substantial burn relative to revenue.
Total assets have fluctuated in the mid-to-high hundreds of millions in 2025 (e.g., around $0.6B–$0.74B across the period), reflecting ongoing asset growth and adjustments as the company funds operations.

Net income attributable to common shareholders was negative in every 2025 quarter, including Q4 2025 at −$105.403 million and Q3 2025 at −$90.532 million, signaling continued large losses per period.
Operating cash flow was negative in all 2025 quarters (Q4 2025: −$81.481 million; Q3 2025: −$71.752 million; Q2 2025: −$64.233 million; Q1 2025: −$61.652 million), highlighting sustained cash burn from operations.
Retained earnings deficit remains substantial (approximately −$1.14 billion by early 2025), underscoring a long-running equity-funded burn and insufficient cumulative profits to date.

05/05/26 08:01 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Xenon Pharmaceuticals' Financials

When does Xenon Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Xenon Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Xenon Pharmaceuticals' net income changed over the last 10 years?

Xenon Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$345.91 million in 2025, rising from -$15.75 million in 2015. The previous period was -$234.33 million in 2024. Check out Xenon Pharmaceuticals' forecast to explore projected trends and price targets.

What is Xenon Pharmaceuticals' operating income?

Xenon Pharmaceuticals' total operating income in 2025 was -$373.07 million, based on the following breakdown:

Total Gross Profit: $7.50 million
Total Operating Expenses: $380.57 million

How has Xenon Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Xenon Pharmaceuticals' total revenue changed from $15.58 million in 2015 to $7.50 million in 2025, a change of -51.9%.

How much debt does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals' total liabilities were at $51.40 million at the end of 2025, a 18.9% increase from 2024, and a 1,663.4% increase since 2015.

How much cash does Xenon Pharmaceuticals have?

In the past 10 years, Xenon Pharmaceuticals' cash and equivalents has ranged from $17.10 million in 2016 to $199.16 million in 2025, and is currently $199.16 million as of their latest financial filing in 2025.

How has Xenon Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Xenon Pharmaceuticals' book value per share changed from 4.25 in 2015 to 7.53 in 2025, a change of 77.3%.

Related Companies

Financial statements for NASDAQ:XENE last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Xenon Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Financials

Annual Income Statements for Xenon Pharmaceuticals

Quarterly Income Statements for Xenon Pharmaceuticals

Annual Cash Flow Statements for Xenon Pharmaceuticals

Quarterly Cash Flow Statements for Xenon Pharmaceuticals

Annual Balance Sheets for Xenon Pharmaceuticals

Quarterly Balance Sheets for Xenon Pharmaceuticals

Annual Metrics And Ratios for Xenon Pharmaceuticals

Quarterly Metrics And Ratios for Xenon Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Xenon Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools